We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+20.6%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$63.1M
AUM Growth
-$19.4M
Cap. Flow
-$10.3M
Cap. Flow %
-16.33%
Top 10 Hldgs %
86.31%
Holding
30
New
4
Increased
1
Reduced
3
Closed
10

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$2.03M
2
AMRN
Amarin Corp
AMRN
+$1.26M

Top Sells

Rank Stock Value
1
ANIP icon
ANI Pharmaceuticals
ANIP
+$9.07M
2
AORT icon
Artivion
AORT
+$3.78M
3
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
+$749K

Sector Composition

Rank Sector Weight
1 Healthcare 84.51%
2 Miscellaneous 15.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRI
26
CALL
DELISTED
Albany Molecular Research Inc
AMRI
– –
-50,000
Closed -$672K
QLTI
27
CALL
DELISTED
QLT Inc
QLTI
– –
-100,000
Closed -$142K
SGNT
28
CALL
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
– –
-35,000
Closed -$524K
SGNT
29
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
– –
-50,000
Closed -$749K
ARLZ
30
CALL
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
– –
-75,000
Closed -$248K
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Healthcare Value Capital held 30 positions worth $63.1M, down 23% from $82.5M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Healthcare Value Capital withdrew a net $10.3M in Q3 2016, closing 10 positions and reducing 3 holdings. Its most notable exit was SAGENT PHARMACEUTICALS INC COM STK (DE), an estimated $749K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 64% a quarter earlier, followed by Miscellaneous.

Against the trend, Healthcare Value Capital opened a new position in Gilead Sciences worth $1.98M.

  • Healthcare Value Capital's largest Q3 2016 buy was Gilead Sciences: 25,000 shares worth $1.98M.
  • Healthcare Value Capital's biggest Q3 2016 reduction was ANI Pharmaceuticals, cutting an estimated $9.07M.
  • Healthcare Value Capital fully exited SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2016, selling an estimated $749K.
  • Healthcare Value Capital's ten largest holdings make up 86% of its $63.1M portfolio in Q3 2016.
  • Healthcare Value Capital opened 4 new positions and closed 10 in Q3 2016.
  • Healthcare Value Capital's portfolio value fell 23% quarter-over-quarter to $63.1M.

Based on Healthcare Value Capital's 13F filing for Q3 2016, filed 10 Nov 2016.